{"filings":[{"id":1582760,"accession_number":"0001171843-26-004582","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2026-07-10T21:00:17+00:00","items":["1.01","9.01"],"status":"ready","headline":"Solésence settles dispute with Refy Beauty for £700,000; agrees to six-month exclusivity for SPF product development","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Solésence to pay Refy £700,000 (~$938,000) in 12 monthly installments starting Aug 5, 2026.","Settlement resolves disputes over consumer care products supplied under a June 2024 contract manufacturing agreement.","Parties agree to six-month exclusivity period for development of a new SPF product; if new supply agreement signed, last six installments credited.","No admission of liability; each party bears own legal costs.","Agreement includes mutual release of claims and confidentiality provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22844,"accession_number":"0001171843-26-003273","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2026-05-12T12:15:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solésence Q1 revenue $13.0M (-11% YoY); net loss $0.8M vs prior-year profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $13.0M vs $14.6M in Q1 2025; gross margin improved to 26% from 23%.","Net loss of $0.8M compared to net income of $0.08M a year ago.","Progress on Transform & Transcend initiative: operational excellence and new platform techs WHSPR and Chromalüm.","Added Marc James as independent director; CFO cites infrastructure investments pressuring near-term profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":12957000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99404,"accession_number":"0001171843-26-002802","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Solésence appoints Marc James as independent director to board and three committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Marc James appointed as Class II Director effective April 24, 2026, term expires at 2026 Annual Meeting.","James will serve on Audit and Finance, Compensation, and Nominating and Corporate Governance Committees.","James brings capital markets expertise from senior managing director roles in global financial markets.","CEO Kevin Cureton cites James's strategic insight and capital markets expertise as valuable for growth strategy.","Board Chair Janet Whitmore notes the appointment expands board expertise for disciplined execution and growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115382,"accession_number":"0001171843-26-002061","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solésence FY2025 rev $62.1M (+19%), net income drops to $1.8M from $4.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year revenue $62.1M, up 19% YoY; net income $1.8M vs $4.2M in 2024.","Q4 revenue $12.5M (flat); gross margin improved to 27% from 22%; net income $0.2M vs loss $0.6M.","Launched Transform & Transcend initiative focusing on operational excellence and globalization.","Appointed Yoolie Park as VP Brand Partnerships; added 20 new beauty brand partners.","Expanded patent portfolio to 16 patents including Kleair™ skin health technology."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":12957000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131792,"accession_number":"0001171843-25-007730","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Solésence enters separation agreement with former CEO Jess Jankowski; $366,912 severance plus option acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Former CEO Jess Jankowski to receive $366,912 severance over 52 weeks plus accelerated vesting of all outstanding options.","Company to pay COBRA health insurance premiums for up to 12 months following November 30, 2025.","Jankowski released all claims against Solésence and reaffirmed confidentiality, non-competition, and non-solicitation obligations.","Jankowski also agreed to cooperate with the Company in future matters and to a non-disparagement clause.","Jankowski resigned as officer and director effective November 21, 2025; agreement dated November 24, effective December 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131791,"accession_number":"0001171843-25-007680","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Solesence: Jess Jankowski retires from board, enters consulting agreement; Cureton appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jess Jankowski retired from Board effective Nov 21, 2025; CEO Kevin Cureton appointed to fill his Class III term.","Jankowski entered consulting agreement effective Nov 22, 2025: up to 80 hours at $177/hour for management, SEC filing support.","Consulting term ends upon 80 hours used, or earlier on 5 days notice, no later than Nov 21, 2026.","Jankowski reaffirms confidentiality, non-compete, and insider trading obligations under prior separation agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131790,"accession_number":"0001171843-25-007246","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solésence Q3 revenue falls 14% YoY to $14.5M; net loss $1.1M vs prior-year profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $14.5M vs $16.9M in Q3 2024; net loss $1.1M vs net income $3.0M.","Gross margin dropped to 23% from 36%; gross profit $3.4M vs $6.1M.","Promoted Kevin Cureton to CEO, appointed Laura Riffner as CFO, and Yoana Dvorzsak as VP Innovation & Product Integrity.","Consolidated manufacturing from three to two facilities; increased production automation."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":49581000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131789,"accession_number":"0001999371-25-017120","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Solésence settles product dispute with Solarium; $675,000 payment due by Jan 15, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement resolves disputes over skin care products Solésence manufactured for Solarium.","Solarium to pay $675,000 one-time settlement on or before January 15, 2026.","If payment is not received, Solésence may obtain a confession of judgment for the full amount plus interest.","Agreement includes mutual release of all claims and confidentiality and non-disparagement obligations.","Agreement dated and effective October 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148388,"accession_number":"0001999371-25-012518","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Solésence appoints Kevin Cureton as CEO, Laura Riffner as CFO; Jankowski advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Cureton, formerly COO, promoted to President and CEO effective Sept 3, 2025; base salary ≥ $367,000.","Laura Riffner named CFO; annual base salary ≥ $270,000; previously CFO at Nagase America.","Jess Jankowski, CEO since 2009, transitions to Board Advisor until retirement on Nov 21, 2025.","Leadership changes follow rebrand from Nanophase Technologies and Nasdaq uplisting in April 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148387,"accession_number":"0001999371-25-012350","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Solesence shareholders elect directors, approve 2025 equity plan, ratify RSM US LLP as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two director nominees elected: R. Janet Whitmore (55,548,531 votes for) and Laura M. Beres (55,853,069 votes for); broker non-votes 4,637,430.","2025 Equity Compensation Plan approved: 56,301,567 for, 207,542 against, 59,368 abstentions, with 4,637,430 broker non-votes.","Ratification of RSM US LLP as independent auditor for 2025: 61,074,473 for, 122,447 against, 8,987 abstentions.","Quorum achieved with 61,205,907 shares (86.83% of outstanding) present at the August 28, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148386,"accession_number":"0001171843-25-004923","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solésence Q2 revenue jumps 56% to $20.4M; net income $2.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $20.4M vs $13.0M in Q2 2024, a 56% increase.","Net income $2.7M vs $0.9M; includes $1.2M Employee Retention Credit net receipt.","Gross profit $5.9M, gross margin 29%, flat YoY.","Shipment volume +102% YoY; production volume +127% YoY.","Expanded debt facilities to $23.0M max, maturity extended to April 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":34984000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167174,"accession_number":"0001999371-25-007401","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Solésence corrects certificate to add accent mark in company name","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed certificate of correction on June 3, 2025 to add an accent over the first 'e' in Solésence.","No changes beyond the accent correction; name previously amended from Nanophase Technologies on March 10, 2025.","Effective date of correction is June 3, 2025; stock ticker remains SLSN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167173,"accession_number":"0001999371-25-006971","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Solésence increases debt facilities to $23M, extends maturity to April 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amended three loan agreements with affiliates of controlling shareholder Bradford T. Whitmore on May 27, 2025.","Maximum borrowing capacity raised from $14.2M to $23.0M; maturity extended from Oct 1, 2025 to Apr 30, 2027.","Revolving loan facility increased from $5.2M to $10M; A/R loan facility from $8M to $12M.","Proceeds for working capital, raw material procurement, packaging lead time improvement, and brand partner support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167172,"accession_number":"0001171843-25-002902","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solésence reports record Q1 revenue $14.6M, up 48% YoY; net income breakeven vs $0.9M profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q1 revenue $14.6M, +48% YoY; gross margin 23% vs 36% due to one-time start-up costs.","Shipment volume +95% YoY; production volume +120% to prepare for Q2 demand.","Backlog of shipped and open orders exceeds $45M; new brand partner drove multi-SKU launch.","Net income breakeven vs $0.9M profit in Q1 2024; expects margin improvement as operations scale.","Nasdaq uplisted under SLSN; IP expanded with allowances in Japan, South Korea, Mexico."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":14625000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167171,"accession_number":"0001171843-25-002068","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["7.01","9.01","8.01"],"status":"ready","headline":"Solesence announces uplisting to Nasdaq Capital Market, trading begins April 8 under ticker SLSN","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shares to trade on Nasdaq effective April 8, 2025; prior OTCQB ticker was NANX.","Uplisting approved after meeting all Nasdaq Capital Market listing requirements.","New ticker symbol SLSN; no shareholder action required.","Audit and Finance Committee reconstituted with Laura Beres (Chair) and Mark Miller.","Management cites increased visibility and potential to scale profitability as benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184534,"accession_number":"0001171843-25-001738","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solésence reports record full-year 2024 revenue of $52.3M, net income of $4.2M vs loss in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $12.6M (+57.5% YoY); gross profit $2.8M (22% margin) vs $0.5M (6%) in Q4 2023.","FY 2024 revenue $52.3M (+40% YoY); net income $4.2M vs net loss $4.4M in FY 2023.","Company rebranded as Solésence; plans to pursue NASDAQ uplisting and search for dedicated CFO in 2025.","Initiated expanded batch-making capacity at Bolingbrook facility to support over $200M annual revenue.","Launched over two dozen new SKUs in prestige and mass beauty; Au Lait Face Milk SPF 50+ won C&T Allē Award."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184533,"accession_number":"0001171843-25-001429","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Nanophase Technologies changes name to Solesence, Inc. effective March 10, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed from Nanophase Technologies Corporation to Solesence, Inc. effective March 10, 2025.","Rebranding underscores success of beauty science platform and commitment to skin health innovation.","Certificate of Amendment filed with Delaware Secretary of State; no other corporate changes.","Company cites new chapter in commitment to innovation, self-expression, and inclusivity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184532,"accession_number":"0001839882-25-002542","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Nanophase shareholders approve increase in authorized common stock from 60M to 95M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders at June 18, 2024 Special Meeting voted 39,837,787 for, 2,008,409 against to raise authorized shares from 60M to 95M.","Certificate of Amendment filed with Delaware on June 19, 2024 and effective that same day.","Approximately 76% of 54,860,984 outstanding shares were represented at the meeting, forming a quorum.","No other matters were submitted to a vote at the Special Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201110,"accession_number":"0001839882-24-046971","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nanophase shareholders elect Jankowski and Miller as directors, ratify RSM US LLP as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jess A. Jankowski re-elected with 54,280,750 votes for, 34,768 withheld.","Mark E. Miller re-elected with 54,300,526 votes for, 14,992 withheld.","Ratification of RSM US LLP as independent auditor approved: 54,297,821 for, 13,101 against, 4,596 abstain.","Approximately 77.6% of 69,994,979 outstanding shares were present or represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201109,"accession_number":"0001171843-24-005894","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nanophase reports record Q3 revenue $16.9M, net income $3M; Solésence revenue up 171%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $16.9M (+112% YoY); net income $3.0M vs loss of $1.4M in Q3 2023.","Solésence segment revenue $13.6M (+171% YoY), driving overall growth.","Gross profit $6.1M (+299% YoY); gross margin expanded to 36% from 19%.","Nine-month revenue $39.8M already exceeds full-year 2023 revenue by $2.5M.","Operational: record units shipped, added automation, expanded to 8 ISO 6 clean rooms."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":39780000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217127,"accession_number":"0001171843-24-004480","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nanophase reports record Q2 revenue $13M (+10% YoY) and net income $856K (+157%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $13M vs $11.9M in Q2 2023 (+10%); Solésence revenue $11.2M (+44% YoY).","First half 2024 net income $1.7M vs loss $0.8M in H1 2023; gross profit $7.3M (+26%).","Second half revenue expected to exceed first half by more than 20% per management.","Won third consecutive Cosmopack North America Formulation Award for Lip Oil SPF 40+.","Q2 net income $856K vs $333K in prior year period, a 157% increase."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":22914000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236899,"accession_number":"0001171843-24-002152","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nanophase reports record Q1 revenue $9.9M, net income $0.9M vs loss, BASF litigation resolved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $9.9M (+4% YoY); net income $0.9M vs net loss of $1.2M in Q1 2023.","Gross margin improved to 36% from 23% YoY; Solésence product revenue contributed $8.0M.","BASF litigation amicably resolved; company expects breakout year with $40M+ in shipped/open orders.","Three consecutive profitable months (Jan-Mar 2024); margin expansion due to improved product mix."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":9868000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236898,"accession_number":"0001171843-24-001961","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["1.01","7.01","9.01","8.01"],"status":"ready","headline":"Nanophase settles BASF exclusivity litigation, amends supply agreement","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Mutual release of all claims in BASF v. Nanophase (NJ Super. Ct. MRS-L-1396-22); case dismissed with prejudice.","Amendment No. 5 clarifies exclusivity: BASF retains field exclusivity for zinc oxide, but Nanophase and Solésence can sell finished products and certain dispersions.","Binding MOU commits Nanophase to develop a modified zinc oxide product for BASF's exclusive purchase (commercially reasonable efforts).","Parties covenant not to sue on settled claims, agree to non-disparagement and confidentiality (subject to SEC disclosure).","Management expects continued growth in API and Solésence finished products with legal uncertainty resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254500,"accession_number":"0001171843-24-001508","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nanophase Q4/FY2023 revenue flat at $37.3M; net loss widens to $4.4M; secures $6M financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $8.0M (vs $8.3M YoY); full-year revenue $37.3M flat; net loss $4.4M ($0.09/sh) vs $2.6M in 2022.","Solésence revenue grew 9% to $25.2M; Personal Care Ingredients fell 17% to $9.3M; Advanced Materials fell 9% to $2.8M.","Closed $6M financing package in March 2024 to support working capital and growth.","Litigation costs contributed $1.3M to operating loss; company expects lower costs and positive resolution ahead.","Management expects $35M in shipped and open POs so far in 2024, with more orders expected in Q2-Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254499,"accession_number":"0001999371-24-003109","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["1.01","2.02","9.01","3.02","3.03","5.03"],"status":"ready","headline":"Nanophase raises $6M in convertible preferred; Q4 revenue $8M, net loss $2.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Issued 15,000 Series X Preferred shares at $400 each to Strandler, LLC, affiliate of largest shareholder.","Preferred convertible into 15M common shares at $0.40/share, pending shareholder approval to boost authorized shares to 95M.","Strandler and Beachcorp extended maturity of three existing loans to October 1, 2025.","Q4 2023 revenue $8.0M, net loss $2.1M; FY2023 revenue $37.3M, net loss $4.4M (30% from BASF lawsuit legal fees)","CEO expects 2024 profitable; company had $30M in completed shipments and confirmed purchase orders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271975,"accession_number":"0001171843-23-007054","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nanophase withdraws 2023 profitability outlook; Q3 revenue hurt by supply chain issues","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Nine-month revenue $29.3M vs $29.1M YoY; Q3 revenue down due to supply chain constraints.","No longer expects modest profitability for 2023; cites cash management focus during Q3.","Closed $3.2M financing: $2.0M bridge loan and $1.2M revolver expansion to support operations.","Solésence won BeautyMatter NEXT Award; Kleair™ nominated for Chicago Innovation and Allē Awards.","Harrison King promoted to VP of Operations; new Purchasing Manager hired in November."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":29286000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288824,"accession_number":"0001171843-23-004897","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nanophase reports record Q2 revenue $11.9M, up 10% YoY; sees Q3 profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $11.9M (+10% product revenue YoY); H1 revenue $21.3M (+12% product revenue YoY)","Gross margin 31% in Q2, up from prior periods; net income before litigation costs 7% (Q2) and 1% (YTD)","Expects Q3 profit and modest full-year profit; $15M in open orders/P.O.s, >2/3 for Q3 volume","Won Cosmopack Formulation Award in July for Natural Glow Face Oil SPF 40+; Harrison King joined as VP manufacturing","First fully automated filling line validated, increasing capacity 200% with no additional labor costs"],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":21329000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288823,"accession_number":"0001171843-23-004587","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2023-07-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Mark E. Miller appointed to Nanophase Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed as independent director effective July 19, 2023.","Will serve on Nominating & Governance, Audit & Finance, and Compensation committees.","Miller brings 36 years of specialty materials and chemicals experience; former President & COO of Nagase Specialty Materials NA LLC.","CEO Jess Jankowski stated Miller will strengthen governance and strategic guidance for skin health markets expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309498,"accession_number":"0001171843-23-003227","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nanophase posts record Q1 revenue of $9.5M, up 16% YoY; gross margin improves 4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 revenue $9.5M vs $8.2M in Q1 2022, a 16% increase.","Gross margin improved 4% quarter-over-quarter, with 2% from labor savings.","March achieved lowest labor cost as a percent of sales since 2021.","Combined $20M in open P.O.s and shipped orders; two-thirds expected as Q2 volume.","Company expects to deliver quarterly profits going forward leading to profitable 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":9457000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309497,"accession_number":"0001839882-23-012008","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Nanophase enters $1.75M note with affiliate of majority shareholder for Bolingbrook facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $1.75M non-revolving line of credit from Beachcorp, LLC (affiliate of majority owner Bradford T. Whitmore) at Prime + 0.75%.","Note matures Sept 30, 2023; proceeds fund clean room and tenant improvements at 400 Crossroads Pkwy, Bolingbrook, IL.","Principal must be prepaid from any landlord reimbursements received under the December 2021 lease.","Note secured by all unencumbered assets; related-party transaction due to Whitmore family ownership.","No financial statements or other exhibits provided beyond the promissory note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328217,"accession_number":"0001171843-23-001979","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nanophase reports record FY2022 revenue $37.3M (+27% YoY) but net loss of $2.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 revenue $37.3M, up 27% YoY; Q4 revenue $8.3M, up 12% YoY.","Net loss $2.6M ($0.05/sh) vs net income $2.3M ($0.05/sh) in 2021.","Solésence revenue $23.1M (+27%); Personal Care Ingredients $11.1M (+44%); Advanced Materials $3.1M (-14%).","Atypical expenses $1.6M: $0.7M cyber theft loss, $0.4M litigation legal fees, $0.3M bad debt.","Received US patent allowance for Kleair skin health tech; named No.2 in Fast Company Beauty innovation list."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345873,"accession_number":"0001171843-22-007244","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nanophase Q3 revenue up 22% to $9.7M; reports $0.75M loss from costs and cyber theft","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 revenue $9.7M (+22% YoY); nine-month revenue $29.1M (+31% YoY).","Solésence revenue $5.9M (+30% YoY); Personal Care Ingredients $2.9M (+34% YoY).","Q3 net loss $0.75M includes $0.19M from cyber theft; total cyber theft loss $0.66M in Sep/Oct.","Expects 7-figure annualized reduction in manufacturing expenses over next quarters.","Kleair technology won Most Significant Ingredient at Cosmetics & Toiletries Allē Awards."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":29056000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362292,"accession_number":"0001387131-22-009591","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2022-09-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BASF sues Nanophase over exclusivity breach; Nanophase files counterclaim for declaratory judgment","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["BASF filed complaint in NJ Superior Court alleging breach of exclusivity provisions in Zinc Oxide Supply Agreement.","Nanophase filed declaratory judgment action in Illinois court, seeking clarification that exclusivity does not cover Solésence products.","Management believes BASF claims are without merit and expects to prevail; seeks to negotiate resolution.","CEO states Solésence IP is exclusively owned and not impacted by BASF complaint; growth potential unencumbered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362291,"accession_number":"0001171843-22-005699","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2022-08-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nanophase reports record Q2 2022 revenue of $11.2M, up 58% YoY; Solésence revenue up 58%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $11.2M, a record, up 58% from $7.1M in Q2 2021.","Solésence revenue $7.1M (+58% YoY); Personal Care Ingredients $3.3M (+86% YoY).","Six-month revenue $19.4M, up 37% from $14.2M in prior year.","Over 40 new products shipped and 20 new brand partners added in Q2.","June 2022 was highest monthly revenue in company history at ~$4.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":19378000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381824,"accession_number":"0001171843-22-003568","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nanophase reports record Q1 revenue of $8.2M, up 15% YoY; guides to >$40M for FY2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $8.2M vs $7.1M prior year (+15%); Solésence revenue $5.6M (+29% YoY).","Personal Care Ingredients revenue $2.4M (+71%); API sales up 70% YoY.","18 new products shipped in Q1; 30 new hires across manufacturing, supply chain, commercial.","Record monthly revenue of ~$3.8M in March; over 1M finished goods units shipped in Q1.","Management expects 2022 revenue to exceed $40M, dependent on operational improvements."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":8156000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399795,"accession_number":"0001171843-22-002230","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2022-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nanophase posts record FY2021 revenue $29.5M, up 70% YoY; Q4 net loss $0.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 revenue $29.5M (70% YoY growth); net income $2.3M ($0.05/sh) vs $1.0M ($0.03) in 2020.","Solésence revenue $18.2M (+170%); API revenue $7.7M (+40%); Advanced Materials $3.6M (-27%).","Q4 2021 revenue $7.4M (+50% YoY); net loss $0.4M vs net income $0.2M in Q4 2020.","Backlog of $33M in shipped/open purchase orders for 2022; Q1 2022 revenue expected above $7M.","Leased 260,000 sq ft facility; added over two dozen team members; TGA GMP clearance for Australia."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":8156000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399794,"accession_number":"0001387131-22-001217","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2022-02-02T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Nanophase Technologies amends loan agreements, increases credit facilities to $12M and extends maturity to 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["A/R Revolver facility limit raised from $6M to $8M; new Inventory facility of up to $4M added","Maturity of A/R Revolver and Term Loan extended from March 2022/2023 to March 2024","Interest rate on borrowings reduced to prime plus 0.75% from prime plus 2% and 5.25% previously","Term loan remains at $1M; all facilities secured by company assets, subordinated to Libertyville Bank line","Loans provided by affiliates of majority stockholder Bradford T. Whitmore (Beachcorp LLC and Strandler LLC)"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418774,"accession_number":"0001387131-21-011887","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2021-12-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Nanophase enters 10-year lease for 222,935 sq ft; initial monthly rent ~$94,747 with six-month abatement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease term from Dec 31, 2021 to May 31, 2032; Premises expandable to 260,890 sq ft on Nov 1, 2022.","Initial base rent $94,747/mo abated entirely Dec 2021–May 2022; after expansion $110,878/mo with 2.75% annual increases.","Security deposit of $500,000 in letter of credit, reducible by 50% after 60th rental payment.","Premises initially for Solésence filling/assembly and company-wide warehousing; additional operations may migrate.","Tenant pays proportionate share of operating expenses, taxes, and utilities; late fee 5% of overdue rent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418773,"accession_number":"0001171843-21-007467","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nanophase Q3 revenue $7.9M up 80% YoY; nine-month net income $2.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $7.9M vs $3.9M YoY; nine-month revenue $22.1M vs $12.3M.","Nine-month net income $2.7M ($0.04 EPS gain) vs $0.8M in 2020.","Solésence beauty science nine-month revenue $13.4M, up 204% YoY, exceeding full-year 2020.","Personal Care Ingredients revenue $5.3M (+28%); Advanced Materials $3.4M (-8%).","Purchase orders in hand for $27M+; ~$10M applies to 2021 orders."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":22110000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436370,"accession_number":"0001171843-21-006007","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2021-08-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nanophase reports record Q2 revenue of $7.1M; Solésence beauty science revenue up 210% YoY to $8.8M in H1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q2 revenue $7.1M vs $4.3M in Q2 2020 (YoY +65%).","H1 2021 revenue $14.2M (+69% YoY); net income $1.4M compared to $0.4M.","Solésence beauty science H1 revenue $8.8M, up 210% from $2.8M, exceeding full-year 2020.","PPP loan $1.0M forgiven by SBA; non-cash interest $0.9M from conversion of related party loan.","Cash at quarter end $1.1M; purchase orders >$20M, half expected to ship in H2 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":14186000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436369,"accession_number":"0001171843-21-005988","cik":883107,"company_name":"SOLESENCE, INC.","ticker":"SLSN","form_type":"8-K","filed_at":"2021-08-16T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Nanophase restates Q1 2021 financials over PPP loan forgiveness timing; cites material weakness","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board determined Q1 2021 10-Q requires restatement to reflect PPP loan forgiveness; original filing no longer reliable.","PPP loan forgiveness approved Feb 2021 but notice received June 2021; gain to be reclassified to other income for Q1.","Material weakness identified in management review controls related to PPP loan forgiveness; corrective measures planned.","Company will file Form 10-Q/A to restate Q1 2021 consolidated financial statements.","Principal executive officer discussed matters with Board and independent auditor RSM US LLP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":88996883.41463415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}